Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Multicentre Efficacy and Safety Study Comparing 10 Mons vs 4 Mons Degarelix Therapy in Prolonging the Off Treatment Interval in Men With Localized Prostate Cancer Receiving Intermittent ADT for Biochemical Recurrence Following Radical Local Therapy

NCT01512472 is registered in ClinicalTrials.gov with Canadian Urology Research Consortium as lead sponsor.

NCT NCT01512472
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01512472 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Multicentre Efficacy and Safety Study Comparing 10 Mons vs 4 Mons Degarelix Therapy in Prolonging the Off Treatment Interval in Men With Localized Prostate Cancer Receiving Intermittent ADT for Biochemical Recurrence Following Radical Local Therapy
Lead sponsor
Canadian Urology Research Consortium
Phase
Phase 4
Overall status
Terminated
Start date
January 31, 2012
Completion date
January 31, 2018
Enrollment
144 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer recurrent